Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aventis/Genta Genasense meeting confirmed

Executive Summary

Date for review of Aventis/Genta's antisense drug Genasense by FDA's oncologic committee has been confirmed for May 3. Genta said it would receive an early May review by the committee (1"The Pink Sheet" Feb. 16, 2004, p. 6). The meeting will begin at 8 a.m. at the Hilton in Gaithersburg, Md...

You may also be interested in...

Aventis/Genta Genasense NDA Expected To Go Before ODAC In May

Aventis and Genta's antisense drug Genasense for treatment of advanced melanoma is expected to be reviewed by FDA's Oncologic Drugs Advisory Committee May 3

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

Coronavirus Update: J&J’s Single Shot Could Catch Up With Frontrunners

Company is confident that data readout from pivotal trial could be ready before the end of 2020.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts